-
Article
Erratum: Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition
Correction to: Leukemia (2017) 31, 1023–1038; doi:10.1038/leu.2017.43; published online 17 February 2017 Following the publication of this article, the editors noted that Janus should be capitalized. The corre...
-
Article
An unusual, activating insertion/deletion MPL mutant in primary myelofibrosis
-
Article
Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile janus kinase inhibition
Janus kinases (JAKs) are required for cytokine receptor signaling. Since the discovery of the highly prevalent JAK2 V617F mutation in myeloproliferative neoplasms (MPNs), JAK2 became a prime target for inhibit...
-
Article
Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin
-
Article
Open AccessThrombopoietin receptor is required for the oncogenic function of CALR mutants
-
Article
Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms
-
Article
Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution
-
Article
Aberrant signal transduction pathways in myeloproliferative neoplasms
The BCR-ABL-negative myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF), entered the spotlight in 2005 when the unique somatic acquired JAK...
-
Article
Introduction to ‘A special spotlight review series on BCR–ABL-negative myeloproliferative neoplasms’